Subclinical Hypothyroidism and Weight
Subclinical hypothyroidism is a mildly raised TSH with a normal free T4, and although it is common in people carrying excess weight, treating it with levothyroxine does not produce meaningful weight loss.
Plain English
Patient-Friendly Explanation
The thyroid gland sets the pace of metabolism. When it produces too little hormone, the pituitary gland responds by raising thyroid-stimulating hormone, or TSH. In subclinical hypothyroidism, TSH is raised while free T4, the main hormone the thyroid makes, is still normal. About half of the people with a mildly raised TSH, somewhere between 4 and 10, turn out to have a normal result when the test is repeated a few months later, so the first step is always to repeat the test rather than start a tablet. There is a genuine association with body weight: obesity is more common in people with a mildly raised TSH, and the relationship appears to run in both directions, because fat tissue itself nudges TSH upward. The question people usually ask next is whether treatment helps them lose weight, and the honest answer is that it does not help meaningfully. In the TRUST trial, which randomised 737 people aged 65 and over with subclinical hypothyroidism to levothyroxine or to a placebo, there was no effect on weight, waist circumference or body mass index. A pooled analysis of randomised trials found the body mass index difference between treatment and placebo was about 0.2, with the confidence interval crossing zero. The people who do benefit from treatment are those with a TSH above 10, or with clear symptoms, positive thyroid antibodies, or a plan for pregnancy, and they benefit in energy and wellbeing rather than on the scales. So a raised TSH is worth investigating properly, and it belongs in the assessment of unexplained weight change, but it is rarely the explanation for excess weight and it is not a route to losing it.
Medical
Clinical Definition
Subclinical hypothyroidism is defined as a serum thyrotropin above the assay reference range with a free thyroxine within range; the conventional upper reference limit is approximately 4.5 mIU per litre, and values are graded as mildly elevated between 4.5 and 10 mIU per litre or markedly elevated above 10. Prevalence is approximately 3 to 10 per cent in adults, rising to 18 to 20 per cent above the age of 65, and is higher in women. The relationship with adiposity is bidirectional: obesity is associated with modestly higher thyrotropin and slightly higher free triiodothyronine and thyroxine, attributed to leptin-mediated effects on hypothalamic thyrotropin-releasing hormone and to altered deiodinase activity, and weight loss of about 5 to 10 per cent lowers thyrotropin, while genuine thyroid hormone deficiency reduces resting energy expenditure and causes weight gain that is only partly adipose tissue, since fluid and reduced lean mass contribute. A persistently elevated thyrotropin should be confirmed on repeat testing after three to six months, because up to half of mildly elevated results normalise spontaneously. The central question in a weight-management consultation is whether replacement changes weight, and the randomised evidence says it does not. The TRUST trial randomised 737 adults aged 65 or older with thyrotropin between 4.60 and 19.99 mIU per litre and normal free thyroxine to levothyroxine or placebo and found no treatment effect on weight, waist circumference or body mass index, with no difference in the hypothyroid symptom score (between-group difference 0.0, 95 per cent confidence interval -2.0 to 2.1) or the tiredness score (0.4, -2.1 to 2.9); a systematic review and meta-analysis of 15 randomised trials in 1,633 participants reported a pooled body mass index difference of 0.2 (95 per cent confidence interval -0.4 to 0.8). Levothyroxine is recommended where thyrotropin is above 10 mIU per litre on repeat testing, and considered for symptomatic patients, those with positive thyroid peroxidase antibodies, women of reproductive age and younger patients with cardiovascular risk factors, starting at 25 to 75 micrograms daily with dose adjustment by thyrotropin. Observational data linking a thyrotropin at or above 10 with increased coronary events, heart failure and stroke support treating that group, while the age-related rise in thyrotropin and a case-control study suggesting increased mortality with replacement in mild subclinical hypothyroidism argue for restraint above the age of 70. The clinically important messages are that subclinical hypothyroidism should not be offered to patients as the explanation for obesity, that treating it is not a weight-loss intervention, and that intentional weight loss in the presence of treated hypothyroidism requires thyrotropin monitoring because the levothyroxine requirement falls as lean body mass falls.
Key Insight
Why It Matters
A mildly raised thyrotropin is common in people carrying excess weight and normalises on repeat testing in about half of them, but replacing thyroid hormone does not shift weight, so it belongs in the differential rather than in the treatment plan.
Sources
Reviewed against standard medical references.
Medically reviewed by
Family Physician & Registered Acupuncturist, Accord Medical Clinic. MBBS (NUS), Graduate Diploma in Family Medicine (NUS), Graduate Diploma in Acupuncture (Singapore College of TCM).
Last reviewed: September 2026
This page is general health education, not medical advice. Whether any treatment is appropriate for you is a decision made in consultation after assessment.
